Biotime Inc : Biotime Inc- on April 6, co entered into a controlled equity offering sales agreement with cantor Fitzgerald & Co as sales agent . Biotime Inc- under agreement company may offer and sell, through Cantor Fitzgerald, shares of co having aggregate offering price of up to $25 million .Biotime- pursuant to agreement,co may offer and sell through Cantor Fitzgerald,shares of co's common stock with aggregate offering price up to $25 million.
Hangzhou Tigermed Consulting Co Ltd <300347.SZ> : Sees Q1 FY 2017 net profit to increase by 0 to 10 percent, or to be 40.2 million yuan to 44.2 million yuan . Says Q1 FY 2016 net profit was 40.2 million yuan .The reason for the forecast is steady development of business.
Aviragen Therapeutics Inc : Company has retained Stifel, Nicolaus & Company, incorporated to serve as its financial advisor in process . Aviragen therapeutics announces review of strategic alternatives and provides corporate update . Does not have a defined timeline for exploration of strategic alternatives . To explore strategic alternatives that include business combination or merger, in-licensing clinical stage programs, deal or other transaction .Aviragen is not confirming that process will result in any strategic alternative being announced or consummated.
Windtree Therapeutics Inc : Windtree Therapeutics reports fourth quarter 2016 financial results and provides key business updates . Q4 loss per share $0.77 . Q4 revenue $900,000 versus $700,000 .Windtree Therapeutics-existing cash resources sufficient to fund operations through completion of aerosurf phase 2b clinical trial,results in mid-2017.
Takara Bio Inc <4974.T> : Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively . Says units Rubicon Genomics and WaferGen Bio-systems will be dissolved after transaction .Says the company, Takara Bio Inc, is a consolidated subsidiary of Takara Holdings Inc <2531.T>.
Nabriva Therapeutics AG : Nabriva Therapeutics provides business and development update and reports 2016 financial results . Nabriva Therapeutics AG- Expect to complete patient enrollment for leap 2 in Q4 of 2017 . Nabriva Therapeutics AG- Anticipate receiving top-line data for leap 2 in Q1 of 2018 .Nabriva Therapeutics AG - Expect year-end balance will be sufficient to fund our operating expenses and capital expenditures at least into Q2 of 2018.
Apollo Endosurgery Inc : Apollo Endosurgery - in March 2017, co informed by department of justice that co is a subject in federal false claims act investigation . Apollo Endosurgery-government's investigation concerns whether there has been or is violation of false claims act related to marketing of lap-band system . Apollo Endosurgery - believe investigation covers period before and after our acquisition of obesity intervention division of Allergan in Dec. 2013 .Apollo Endosurgery-possible that foregoing matter could result in material adverse effect on business,reputation,results of operation,financial condition.
Ignyta Inc : Ignyta announces exploration of strategic options for Taladegib, enabled by amendment of Taladegib license agreement with Lilly . Ignyta - agreement amends and restates prior license, development and commercialization agreement, dated November 6, 2015, by and between Ignyta, Lilly .Ignyta Inc - entered into amended , restated license, development, commercialization agreement with Eli Lilly and company for Taladegib Oncology program.
Medigene Ag : FY total revenue increases 43 pct to 9.8 million euros ($10.58 million) . Financial guidance for 2016 met . Financial guidance for 2017 reflects Medigene's alignment and continued focus on its core business of immunotherapies . 2017 revenue: planned total revenue in 2017 between 8 - 10 million euros . 2017 projected EBITDA loss of 16 - 18 million euros . For 2017 Medigene anticipates cash utilization of between 23 - 27 million euros, partly due to non-recurring effects such as investments in laboratory infrastructure . FY net loss for year was reduced by 27 pct to 9.492 million euros (2015: 12.999 million euros) .Company has sufficient financial resources to fund business operations well beyond forecast horizon of two years.
Aveo Pharmaceuticals Inc : Aveo Pharmaceuticals says have identified conditions and events that raise substantial doubt about ability to continue as a going concern - SEC filing . Aveo Pharmaceuticals says "continue as a going concern, we must secure additional capital to provide us with additional liquidity" . Aveo Pharma - believe about $23.3 million in existing cash,cash equivalents, securities at Dec. 31, 2016, could allow to fund planned operations into Q4 2017 .Aveo Pharmaceuticals Inc says additional funds will be needed to extend planned operations into 2018.